exceeded 235 thousand shares.Looks like investors have started to lose their interest into the shares of Regenicin.
Last week, the company reported that it has begun to identify candidates for the formation of a Scientific Advisory Board and the latest news on WDST was released just today. It announced that Dr. Gervaise Gerstner, the appointed person to the company’s SA Board, was a board-certified dermatologist and Assistant Clinical Professor of Dermatology at Mount Sinai Hospital in New York, which was taken as a big plus for Regenicin.[BANNER]
But this news wasn’t enough to push up WDST stock price and it began to move down.
Regenicin, Inc. is a development stage company focusing on next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin. Historical data shows that the company used to be at low trade for quite a long time, but since mid-August the stock price started to move up.
As a development stage company, Regenicin has generated no revenues since inception. The big problem is that WDST has neither cash and cash equivalents, nor any assets, though it has liabilities that nobody knows how the company will cover.
As stated in its financial report, Regenicin had negative working capital and no revenues and “These factors create substantial doubt about our ability to continue as a going concern”.
